Journals / MN Kardiyoloji / 2009 / Cilt: 16 - Sayı: 4

Revascularization in patients with ischemic heart disease and severe left ventricular dysfunction: Identification of patients likely to benefit from revascularization

Ciddi sol ventrikül disfonksiyonu olan iskemik kalp hastalarında revaskülarizasyon: Yarar görecek hastaların belirlenmesi

Pages
280–288
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The available data show that revascularization provides survival benefit in selected patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The number of patients with severe left ventricular (LV) dysfunction from coronary artery is increasing and their predominat symptom is heart failure rather than angina.
📊
Key Findings & Data:Thus, it is important to identify ischemic patients with severe LV dysfunction who may benefit from this treatment strategy.
💡
Conclusion & Impact:The available data show that revascularization provides survival benefit in selected patients.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:İskemi · Miyokardiyal revaskülarizasyon · Seyir

Abstract

The number of patients with severe left ventricular (LV) dysfunction from coronary artery is increasing and their predominat symptom is heart failure rather than angina. This case represents a major clinical challenge. Despite therapeutics advances, prognosis of these patients still remains poor. Reversibility of LV dysfunction is a potential benefit. Although revascularization improve outcome of patients with severe LV dysfunction suffering from angina, its role is unclear in the patients whose predominant symptom is heart failure. On the other hand, revascularization has high periprocedural risks. Thus, it is important to identify ischemic patients with severe LV dysfunction who may benefit from this treatment strategy. This review has focused on the current literature regarding the effect of revascularization on clinical outcomes and the role of viability testing and other potential factors. The available data show that revascularization provides survival benefit in selected patients.

Özet

Koroner arter hastalığına bağlı ciddi sol ventrikül (SV) disfonksiyonlu hasta sayısı artmaktadır ve onların baskın semptomu anginadan ziyade kalp yetersizliğidir. Tedavisi de önemli bir medikal sorundur. Terapötik yeniliklere rağmen, bu hastaların progozu hala kötüdür. SV disfonksiyonunun geriye dönüşlü olması potansiyel bir avantajdır. Revaskülarizasyon, anginası olan ciddi SV disfonksiyonlu hastaların klinik sonuçlarını iyileştirirmesine karşın, baskın semptomu kalp yetersizliği olanlarda bu tedavinin rolü belirsizdir. Öte yandan, revaskülarizasyonun riski yüksektir. Bundan dolayı, revaskülarizasyondan yarar görecek hastaların belirlenmesi önemlidir. Bu derlemede, revaskülarizasyonun klinik sonuçlara etkisine, viabilite ve diğer potansiyel faktörlerin rolüne ilişkin güncel bilgiler gözden geçirilmiştir. Seçilmiş hastalarda, revaskülarizasyon sağ kalım avantajı sağlar.

🔖

Cite This Article

DOĞAN, A., TÜRKER, Y., AKÇAY, S. (2009). Revascularization in patients with ischemic heart disease and severe left ventricular dysfunction: Identification of patients likely to benefit from revascularization. MN Kardiyoloji, Cilt: 16 - Sayı: 4, 280–288. https://ajindex.com/articles/297948

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Roger VL, Weston SA, Redfield MM, et al. Trends in heart failure incidence and survival in a community-based population. JAMA 2004
  2. 292(3):344-50. 2.Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (Update 2005). Eur Heart J 2005
  3. 26(11): 1115-40. 3.Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline update for the diagnosis and management of chronic heart Failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2005
  4. 112(12):el54-235. 4.Felker GM, Shaw LK, O'Connor CM. A standardized definition of ischemic cardiomyopathy for use in clinical research. J Am Coll Cardiol 2002
  5. 39(2):210-8. 5.Ghose X Thompson RC. Revascularization for patients with severe coronary artery disease and left ventricular dysfunction. Curr Cardiol Rep 2006
  6. 8(4):255-60. 6.Chareonthaitawee P, Gersh BJ, Araoz PA, Gibbons RJ. Revascularization in severe left ventricular dysfunction. The role of viability testing. J Am Coll Cardiol 2005
  7. 46(4):567-74. 7.Bax JJ. Assessment of myocardial viability in ischemic car-diomyopathy. Heart Lung Circulation 2005
  8. 14(Suppl 2):S8-13. 8.Bax JJ, van der Wall EE, Harbinson M. Radionuclide techniques for the assessment of myocardial viability and hibernation. Heart 2004
  9. 90(Suppl 5):v26-33. 9.Allman KC, Shaw U, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol 2002
  10. 39(7):1151-8. 10.Baker DW, Jones R, Hodges J, Massie BM, Konstam MA, Rose EA. Management of heart failure: the role of revascularization in the treatment of patients with moderate or severe left ventricular systolic dysfunction. JAMA 1994
  11. 272(19):1528-34. 11.Kleikamp G, Maleszka A, Reiss N, Stuttgen B
  12. Korfer R.Determinants of mid- and long-term results in patients after surgical revascularization for ischemic cardiomy-opathy. Ann Thorac Surg 2003
  13. 75(5):1406-12. 12.Dries DL, Sweitzer NK, Drazner MH, Stevenson LW, Gersh BJ. Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction. J Am Coll Cardiol 2001
  14. 38(2):421-8. 13.Rizzello V, Poldermans D, Boersma E, Biagini E, Schinkel AF, Krenning B, et al. Opposite patterns of left ventricular remodeling after coronary revascularization in patients